866-997-4948(US-Canada Toll Free)

Glaucoma - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 280 Pages

Glaucoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H1 2017, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 10, 22, 8, 56, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 5 molecules, respectively.

Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Glaucoma - Overview 7
Glaucoma - Therapeutics Development 8
Glaucoma - Therapeutics Assessment 23
Glaucoma - Companies Involved in Therapeutics Development 35
Glaucoma - Drug Profiles 64
Glaucoma - Dormant Projects 252
Glaucoma - Discontinued Products 257
Glaucoma - Product Development Milestones 259
Appendix 267

List of Tables
Number of Products under Development for Glaucoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Glaucoma - Pipeline by AC Immune SA, H1 2017
Glaucoma - Pipeline by Advanced Refractive Technologies Inc, H1 2017
Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H1 2017
Glaucoma - Pipeline by Allergan Plc, H1 2017
Glaucoma - Pipeline by Altacor Ltd, H1 2017
Glaucoma - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Glaucoma - Pipeline by Amgen Inc, H1 2017
Glaucoma - Pipeline by Annexon Inc, H1 2017
Glaucoma - Pipeline by Astellas Pharma Inc, H1 2017
Glaucoma - Pipeline by Bausch & Lomb Inc, H1 2017
Glaucoma - Pipeline by BioAxone BioSciences Inc, H1 2017
Glaucoma - Pipeline by Bionure Farma SL, H1 2017
Glaucoma - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Glaucoma - Pipeline by Clearside BioMedical Inc, H1 2017
Glaucoma - Pipeline by D. Western Therapeutics Institute Inc, H1 2017
Glaucoma - Pipeline by Dompe Farmaceutici SpA, H1 2017
Glaucoma - Pipeline by Elsalys Biotech SAS, H1 2017
Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Glaucoma - Pipeline by Gene Signal International SA, H1 2017
Glaucoma - Pipeline by Gilead Sciences Inc, H1 2017
Glaucoma - Pipeline by Glaukos Corp, H1 2017
Glaucoma - Pipeline by Graybug Vision Inc, H1 2017
Glaucoma - Pipeline by Han Wha Pharma Co Ltd, H1 2017
Glaucoma - Pipeline by Handok Inc, H1 2017
Glaucoma - Pipeline by Icon Bioscience Inc, H1 2017
Glaucoma - Pipeline by ID Pharma Co Ltd, H1 2017
Glaucoma - Pipeline by InMed Pharmaceuticals Inc, H1 2017
Glaucoma - Pipeline by Inotek Pharmaceuticals Corp, H1 2017
Glaucoma - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
Glaucoma - Pipeline by Isarna Therapeutics GmbH, H1 2017
Glaucoma - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2017
Glaucoma - Pipeline by Laboratoires Thea SA, H1 2017
Glaucoma - Pipeline by Laboratorios SALVAT SA, H1 2017
Glaucoma - Pipeline by Laboratorios Sophia SA de CV, H1 2017
Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
Glaucoma - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
Glaucoma - Pipeline by Merck & Co Inc, H1 2017
Glaucoma - Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017
Glaucoma - Pipeline by Nemus Bioscience Inc, H1 2017
Glaucoma - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
Glaucoma - Pipeline by NicOx SA, H1 2017
Glaucoma - Pipeline by NoNO Inc, H1 2017
Glaucoma - Pipeline by Novaliq GmbH, H1 2017
Glaucoma - Pipeline by Ocular Therapeutix Inc, H1 2017
Glaucoma - Pipeline by Oculis ehf, H1 2017
Glaucoma - Pipeline by Ohr Pharmaceutical Inc, H1 2017
Glaucoma - Pipeline by Profarma, H1 2017
Glaucoma - Pipeline by Q BioMed Inc, H1 2017
Glaucoma - Pipeline by Quark Pharmaceuticals Inc, H1 2017
Glaucoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Glaucoma - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
Glaucoma - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
Glaucoma - Pipeline by Shire Plc, H1 2017
Glaucoma - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Glaucoma - Pipeline by Sun Pharmaceutical Industries Ltd, H1 2017
Glaucoma - Pipeline by Sylentis SAU, H1 2017
Glaucoma - Dormant Projects, H1 2017
Glaucoma - Dormant Projects, H1 2017 (Contd..1), H1 2017
Glaucoma - Dormant Projects, H1 2017 (Contd..2), H1 2017
Glaucoma - Dormant Projects, H1 2017 (Contd..3), H1 2017
Glaucoma - Dormant Projects, H1 2017 (Contd..4), H1 2017
Glaucoma - Discontinued Products, H1 2017
Glaucoma - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures
Number of Products under Development for Glaucoma, H1 2017 20
Number of Products under Development by Companies, H1 2017 21
Number of Products under Development by Universities/Institutes, H1 2017 27
Number of Products by Top 10 Targets, H1 2017 35
Number of Products by Stage and Top 10 Targets, H1 2017 35
Number of Products by Top 10 Mechanism of Actions, H1 2017 39
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 39
Number of Products by Top 10 Routes of Administration, H1 2017 43
Number of Products by Stage and Top 10 Routes of Administration, H1 2017 43
Number of Products by Top 10 Molecule Types, H1 2017 45
Number of Products by Stage and Top 10 Molecule Types, H1 2017 45

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *